Pharmaceutical Preparations · CIK 1404644
Neurogene Inc. develops genetic medicines for rare neurological diseases using proprietary transgene regulation technology
Comparable business profile · signals at a glance
In the 90 days to Mar 26, 2026: 4 sold $494K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 26, 2026 | Mcminn RachelChief Executive Officer | Sell | 3,352 | $22.07 | $74K |
| Mar 26, 2026 | Cvijic Christine MikailPresident and CFO | Sell | 2,558 | $21.62 | $55K |
| Mar 26, 2026 | Jordan JulieChief Medical Officer | Sell | 828 | $21.89 | $18K |
| Mar 13, 2026 | Cobb StuartChief Scientific Officer | Sell | 3,991 | $20.41 | $81K |
| Mar 13, 2026 | Cobb StuartChief Scientific Officer | Sell | 2,658 | $21.34 | $57K |
| Mar 13, 2026 | Cvijic Christine MikailPresident and CFO | Sell | 2,387 | $20.42 | $49K |
| Mar 13, 2026 | Cvijic Christine MikailPresident and CFO | Sell | 1,395 | $21.25 | $30K |
| Mar 13, 2026 | Cvijic Christine MikailPresident and CFO | Sell | 263 | $22.02 | $6K |
| Mar 13, 2026 | Cobb StuartChief Scientific Officer | Sell | 148 | $22.08 | $3K |
| Feb 27, 2026 | Cvijic Christine MikailPresident and CFO | Sell | 4,800 | $25.11 | $121K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.